Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Fibroblast growth factor 2 monoclonal antibody (2H11)

 
ADI-905-833-100 100 µl 357.00 USD
Do you need bulk/larger quantities?
 

Product Specification

Alternative Name:FGF2
 
Clone:2H11
 
Host:Mouse
 
Isotype:IgG1
 
Immunogen:Recombinant human bFGF (fibroblast growth factor 2) (aa 10-155).
 
UniProt ID:Q60487
 
Species reactivity:Human
 
Applications:WB
 
Recommended Dilutions/Conditions:Western Blot (1:10,000)
Suggested dilutions/conditions may not be available for all applications.
Optimal conditions must be determined individually for each application.
 
Application Notes:Detects a band of ~31kDa (full length) by Western blot.
 
Purity Detail:Protein G affinity purified.
 
Formulation:Liquid. In PBS, pH 7.3, containing 1% BSA, 50% glycerol and 0.02% sodium azide.
 
Shipping:Shipped on Blue Ice
 
Long Term Storage:-20°C
 
Scientific Background:bFGF is a member of the fibroblast growth factor (FGF) family. FGF family members bind heparin and possess broad mitogenic and angiogenic activities. This protein has been implicated in diverse biological processes, such as limb and nervous system development, wound healing, and tumor growth. The mRNA for this gene contains multiple polyadenylation sites, and is alternatively translated from non-AUG (CUG) and AUG initiation codons, resulting in five different isoforms with distinct properties. The CUG-initiated isoforms are localized in the nucleus and are responsible for the intracrine effect, whereas, the AUG-initiated form is mostly cytosolic and is responsible for the paracrine and autocrine effects of this FGF.
 
905-833 WB
Western blot analysis: Recombinant human bFGF probed with bFGF mAb (2H11) at 1:10000.
Please mouse over
905-833 WB

Related Literature

Brochures
Stem Cells
Stem Cells
Download as PDF

All new literature pieces

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,